LOGIN  |  REGISTER
Cue Biopharma
Recursion

LeMaitre Vascular to Participate at Upcoming Investor Conferences in March

March 03, 2023 | Last Trade: US$87.79 0.97 1.12

BURLINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in four upcoming investor conferences in March.

35th Annual Roth Conference 2023
Monday, March 13, 2023
The Ritz Carlton, Laguna Niguel located in Dana Point, CA
David Roberts, President, will participate in a fireside chat at 12:30 PM PT (3:30 PM ET)

Oppenheimer 33rd Annual Healthcare Conference (Virtual)
Wednesday, March 15, 2023
JJ Pellegrino, Chief Financial Officer, will present at 8:40 AM ET

Barclays Global Healthcare Conference
Wednesday, March 15, 2023
Loews Miami Beach Hotel, Miami Beach, FL
David Roberts, President, will present at 2:35 PM ET

KeyBanc Life Sciences & MedTech Investor Forum (Virtual)
Wednesday, March 22, 2023
David Roberts, President, will present at 3:00 PM ET

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page